foxo4 dri senolytic human trial Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging Molecular modelling of the FOXO4-TP53
Molecular modelling of the FOXO4 TP53 interaction to design senolytic peptides for the elimination of senescent cancer cells ScienceDirect FOXO4 DRI Peptide Dosing Guide: Senolytic Peptide Protocol (June 2026) FOXO4 DRI 10mg vial Description RCpeptides FOXO4 DRI (FOX04 DRI) 10mg Peptide Luxe Peptides FOXO4 DRI Vial 10mg Stemcode Peptides The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications
Pay in 4 interest-free payments of $5.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5





